VEGF、PCNA在非小细胞肺癌组织中的表达及意义  

Expressions and clinical significances of VEGF and PCNA in non-small cell lung cancer

作　　者：杨宏刚[1] 刘建军[1] 杨敏[1] 

机构地区：[1]新疆阿克苏地区第一人民医院胸外科,新疆阿克苏843000

出　　处：《新疆医科大学学报》2009年第2期159-160,164,共3页Journal of Xinjiang Medical University

摘　　要：目的:探讨血管内皮生长因子(VEGF)、增殖细胞核抗原(PCNA)在非小细胞肺癌(NSCLC)中的表达及其临床意义。方法:采用免疫组化SP法检测了40例非小细胞肺癌和10例正常肺组织中VEGF、PCNA的表达情况,并分析其与临床病理分期的关系。结果:40例非小细胞肺癌的VEGF阳性表达率为72.5%,明显高于正常对照组(20%),差异有统计学意义(P<0.05),但临床Ⅲ～Ⅳ期的VEGF阳性表达率(80%)与Ⅰ～Ⅱ期的表达率(65%)相比,差异无统计学意义(P>0.05)。PCNA在非小细胞肺癌中的阳性表达率为62.5%,明显高于正常对照组(20%),差异有统计学意义(P<0.05),但临床Ⅲ～Ⅳ期的PCNA阳性表达率(65%)与Ⅰ～Ⅱ期的表达率(60%)之间无明显差异(P>0.05)。结论:VEGF和PCNA可以作为评价非小细胞肺癌预后的重要指标。Objective： To investigate （NSCLC）. Methods： The expressions 10 normals by immunohistochemistry the function of VEGF and PCNA in non-small cell lung cancer of VEGF and PCNA were evaluated in 40 specimens of NSCLC and S-P method, and the relationship was analysed between the result and the clinical stage of pathological. Results： The positive rate of VEGF was 72.5%. It has statistically significant difference between normal tissue （20 %） and NSCLC （P 〈0.05）, but no significant difference was found between clinical stage Ⅰ - Ⅱ （65%） and clinical stage Ⅲ-Ⅳ （80%） （P 〉0.05）. The positive rate of PCNA was 62. 5% in NSCLC. It has statistically significant difference between normal tissue （20%） and NSCLC （P〈0. 05）, but no significant difference was found between clinical stage Ⅰ-Ⅱ ~ （60%） and clinical stage Ⅲ-Ⅳ （65%） （P 〉0.05）. Conclusion： VEGF and PCNA may serve as a parameter for predicting recurrence,metastasis and prognosis of lung cancinoma.

关 键 词：非小细胞肺癌 血管内皮生长因子 增殖细胞核抗原 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤] R393.11[医药卫生—临床医学]